Platelet derived growth factor (PDGF) signaling pathway promotes processes of cancer aggressiveness as epithelial mesenchymal transition (EMT), tumor proliferation, growth and progression, angiogenesis, inhibition of apoptosis, recurrence and metastatic dissemination via the activation of various signaling pathway as PI3K/AKT and RAS/MAPK signaling pathways [3–5]. Platelet-derived growth factor receptors (PDGFR) and their ligands were reported as highly expressed in consensus molecular subtypes 4 (CMS4) colon tumors and identified as potential therapeutic targets for this subtype [6]. The gene discussed is PDGFRB; the disease is neoplasm.